Mohamed Morsy

A Cardiologist aspiring to a better world.

Experienced with interventional procedures and patient care management. Utilizes advanced diagnostic techniques and innovative treatment methods to improve patient outcomes. Track record of effective collaboration and adaptability in high-stress situations.

Experienced academic professional with proven track record in delivering engaging and insightful lectures. Adept at curriculum development, research, and fostering inclusive learning environment. Strong focus on collaboration and achieving academic excellence. Reliable and adaptable, with skills in critical thinking, communication.

• Robert Jan, van Geuns, MD, PhD, RobertJan.vanGeuns@radboudUMC.nl, RadboudUMC, Nijmegen, Nijmegen, Netherlands
• Hosam Hasan, El Araby, MD, PhD, hosam_hasan@aun.edu.eg, +2012239713277, Assiut University, Assiut, Egypt
• Lokien, van Nunen, MD, Lokien.vanNunen@radboudumc.nl, RadboudUMC, Nijmegen, Nijmegen, Netherlands

• Implemented advanced techniques in chronic total occlusion and high-risk percutaneous coronary interventions, enhancing patient outcomes.
• Supervised and trained medical residents and students during clinical rounds, improving educational outcomes and clinical skills.
• Participated in a prestigious EAPCI clinical training fellowship, acquiring expertise in interventional cardiology and expanding professional network.
• Contributed to training and development initiatives within the cardiology department, fostering a culture of continuous improvement and innovation.
• Performed or assisted in 120 transcatheter aortic valve implantation (TAVI) procedures, significantly reducing procedure times and improving recovery rates for patients.
• Conducted over 900 cardiac procedures, including a high volume of complex cases leading to enhanced clinical outcomes and patient safety.

• Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial, Euro Intervention 2025;21:910-920 DOI: 10.4244/EIJ-D-24-01065
• Comparison of high-risk characteristics of non-culprit plaques in relation to plaque severity in acute coronary syndrome - Cardiovascular Revascularization Medicine, Volume 75, June 2025, Pages 80-83
• TCT-576 Serum Cholesterol Levels Do Not Influence Lipid Core Burden Index - Journal of the American College of Cardiology September 2022
• Intensive Lipid-Lowering Therapy Directly Post-ACS Increases FFR and Decreases Plaque Size - Cardiovascular Revascularization Medicine July 2022
• CRT-400.16 Intensive Lipid-Lowering Therapy Directly Post-ACS Increases FFR and Decreases Plaque Size - JACC Cardiovascular Interventions February 2022
• Effect of PCSK9 inhibitors on microvascular dysfunction following ACS - E-poster EuroPCR 2025

• Adaptability
• Teamwork
• Communication
• Empathy
• Critical thinking
• Time management
• Problem-solving
• Resilience
• Leadership